- Glaxosmithkline said its ViiV Healthcare joint venture had submitted a marketing authorisation application to the European Medicines Agency for a single-tablet, two-drug regimen for the treatment of HIV.

The submission was based on studies that included more than 1400 infected adults, the results of which were presented at the 2018 International AIDS Society meeting in July.

A new drug application to the US FDA was planned for the single tablet regimen for October.

Other global regulatory submissions of dolutegravir and lamivudine as a single-tablet, two-drug regimen were anticipated in the coming months.

At 1:09pm: [LON:GSK] GlaxoSmithKline PLC share price was -9.7p at 1485.9p

Story provided by